Medtronic PLC is a world-leading medical technology company that develops and manufactures device-based medical therapies to improve patient outcomes. Founded in 1949 in Minneapolis, Minnesota, Medtronic has grown to become one of the largest medical device companies in the world. The company's operational and executive headquarters are in Dublin, Ireland, with over 90,000 employees in more than 150 countries.
Medtronic's portfolio of medical technologies includes products for diagnosing, treating and managing cardiac rhythm disorders and cardiovascular disease, spinal and biologics, diabetes management and neuromodulation. The company's cardiac and vascular group is the oldest and largest business unit, which develops pacemakers, defibrillators and heart valves. Medtronic's spinal and biologics business is the second-largest business unit and produces a range of implants, instruments and services to treat spinal disorders. The diabetes group develops insulin pumps, continuous glucose monitoring systems and consumables. At the same time, the neuromodulation business focuses on therapies to treat chronic pain, movement disorders and other neurological conditions.
In 2015, Medtronic acquired Covidien PLC, an Irish-based medical technology company, and moved its legal headquarters to Ireland. This transaction was the most significant U.S. corporate tax inversion in history and allowed the company to take advantage of lower corporate taxes in Ireland. The company also achieved a 100% gender and ethnically diverse pay equity in the U.S. and 99% gender pay equity globally, as reported in its Global Inclusion, Diversity and Equity 2022 annual report. Medtronic joined the Bloomberg Gender-Equality Index (GEI) in 2023, becoming one of the 483 companies listed in the index.
Medtronic's stock is traded on the New York Stock Exchange (NYSE) under the ticker symbol MDT and is a member of the S&P 500 and the Dow Jones Industrial Average (DJIA). The company has had several recent recalls, including the HeartWare Ventricular Assist Device in February 2021 and the controller ports in June 2021.
Medtronic has continued to focus on developing its medical technology portfolio and announced several acquisitions and partnerships in 2021. In January, the company announced its intention to acquire Affera, Inc., Stimgenics LLC and Medicrea. In May, Medtronic announced a strategic partnership with CathWorks, and in March 2022, a contract with Vizient. The company is also working with GE Healthcare to support the needs and care demands at Ambulatory Surgery Centers in April 2022. In October 2022, Medtronic announced its intention to pursue a separation of the company's combined patient monitoring and respiratory interventions businesses.
Medtronic PLC is a world-leading medical technology company that has grown to become one of the largest medical device companies in the world. With its portfolio of medical technologies and recent acquisitions and partnerships, the company is well-positioned to capitalize on the growth of the medical device industry. The company's commitment to gender and ethnic pay equity and inclusion and its strategic partnerships and acquisitions make Medtronic PLC an attractive option for investors looking for a long-term growth opportunity.
